AstraZeneca’s Enhertu received a positive EU recommendation for residual HER2-positive early breast cancer, after DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death versus T-DM1. For investors, the opinion advances Enhertu toward a potential new early-breast-cancer standard in the EU if approved.

Key Highlights

  • Enhertu was recommended for EU approval as adjuvant monotherapy for adults with resected HER2-positive breast cancer and residual invasive disease after neoadjuvant treatment.
  • DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death versus T-DM1.
  • DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death with Enhertu versus T-DM1.

ASTRAZENECA PLC (NYSE: AZN) is a major pharmaceuticals company. Enhertu has received a positive recommendation in the European Union for adults with residual invasive HER2-positive early breast cancer after neoadjuvant treatment, with DESTINY-Breast05 showing a 53% reduction in invasive disease recurrence or death versus T-DM1. The recommendation is for adjuvant treatment.

EU Recommendation Covers Residual Disease

The opinion drew on the global, randomised, open-label DESTINY-Breast05 Phase III trial. The trial’s primary measure was investigator-assessed invasive disease-free survival.

Trial Results Support Potential Standard of Care

DESTINY-Breast05 produced a hazard ratio of 0.47, with a 95% confidence interval of 0.34-0.66 and p<0.0001. T-DM1 is the current standard of care in the EU for this adjuvant setting among patients with residual invasive disease. Enhertu and T-DM1 were evaluated in patients at high risk of recurrence following neoadjuvant therapy.